Prostate cancer, high-dose-rate (HDR) brachytherapy, radiorecurrent disease.
Conditions
Interventions
Single fraction HDR treatment to a dose of 19 Gray
Sponsors
University Medical Center Utrecht
Eligibility
Inclusion criteria
Inclusion criteria: - Age >18 years; - Biopsy proven local recurrence; - Biopsy proven recurrence at least 2 years after primary radiotherapy treatment (low-dose-rate brachytherapy or external beam radiation therapy); - Limited and non-aggressive tumor presentation at time of salvage (PSA at time of salvage 70; - Written informed consent; - Fit for anaesthesia.
Exclusion criteria
Exclusion criteria: - Distant metastases; - Severe toxicity from primary radiation treatment (IPSS>15); - Patients who meet exclusion criteria for MRI following the protocol of the radiology department of the UMC Utrecht (see appendix); - Anticoagulant administration continuously required, except for Ascal; - Discongruence between prostate biopsies and contrast MR imaging; - Prior prostate treatment(s) (like a recent TURP (<6 months before focal salvage HDR treatment), HIFU, cryosurgery), except for radiotherapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To investigate the occurrence of gastrointestinal and/or genitourinary toxicity after focal salvage HDR-BT for locally recurrent prostate cancer. | — |
Secondary
| Measure | Time frame |
|---|---|
| - To determine the technical feasibility of MRI guided focal HDR-BT as salvage treatment for locally recurrent prostate cancer; - Quality of life; - Biochemical disease free survival (as defined by Phoenix criterium nadir+2) | — |
Contacts
Public ContactJ.R.N. van der Voort van Zyp
UMC Utrecht, Department of Radiotherapy
Outcome results
None listed